In This Article:
Amid heightened global trade tensions and economic uncertainty, European markets have experienced significant declines, with the STOXX Europe 600 Index seeing its largest drop in five years. In such volatile conditions, companies with strong insider ownership can be appealing to investors as this often indicates confidence from those closest to the business.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| Pharma Mar (BME:PHM) | 11.8% | 40.8% |
| Vow (OB:VOW) | 13.1% | 111.2% |
| Elicera Therapeutics (OM:ELIC) | 28.3% | 97.2% |
| Bergen Carbon Solutions (OB:BCS) | 12% | 50.8% |
| Lokotech Group (OB:LOKO) | 13.9% | 58.1% |
| Nordic Halibut (OB:NOHAL) | 29.8% | 56.3% |
| CD Projekt (WSE:CDR) | 29.7% | 36.8% |
| Elliptic Laboratories (OB:ELABS) | 22.6% | 88.2% |
| Ortoma (OM:ORT B) | 27.7% | 68.6% |
| Circus (XTRA:CA1) | 26% | 51.4% |
Let's uncover some gems from our specialized screener.
Moltiply Group
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Moltiply Group S.p.A. is a holding company in the financial services industry with a market cap of €1.42 billion.
Operations: The company's revenue segments include €221.12 million from the Mavriq Division and €232.86 million from Moltiply BPO&Tech.
Insider Ownership: 22.9%
Moltiply Group S.p.A. demonstrates robust growth potential with earnings forecasted to rise significantly at 26.21% annually, outpacing the Italian market's 7.6%. Despite a high debt level, its revenue is projected to grow at 15% per year, surpassing the local market average of 4.1%. Recent financials show an increase in sales from €414.02 million to €469.17 million and net income from €34.69 million to €41.71 million for fiscal year-end 2024, highlighting solid performance momentum without recent insider trading activity influencing stock dynamics.
Getinge
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Getinge AB (publ) is a company that offers products and solutions for operating rooms, intensive-care units, and sterilization departments both in Sweden and globally, with a market cap of SEK52.98 billion.
Operations: Getinge's revenue segments comprise Life Science at SEK4.55 billion, Acute Care Therapies at SEK17.95 billion, and Surgical Workflows (excluding Life Science) at SEK12.26 billion.
Insider Ownership: 20.4%
Getinge shows potential as a growth company with significant insider ownership, despite challenges in profit margins, which decreased from 7.6% to 4.7%. The company's earnings are forecasted to grow significantly at 22.2% annually, outpacing the Swedish market's average of 9.4%. Recent innovations like the Neural Pressure Support for ICU ventilation and DPTE®-FLEX port enhance its product offerings. However, an unstable dividend track record and lower-than-expected return on equity remain concerns.